Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Tissue-based map of the human proteome

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,847

Toxicities of chimeric antigen receptor T cells: recognition and management

Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,033

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706

Sentinel cells enable genetic detection of SARS-CoV-2 Spike proteinPreprint

Weinberg, Z. Y., Hilburger, C. E., Kim, M. J., Cao, L., Khalid, M. M., Elmes, S., Diwanji, D. C., Hernandez, E., Lopez, J., Schaefer, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440678 · Cited by 12

Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager

Zhou, X., Geyer, F. K., Happel, D., Takimoto, J., Kolmar, H., & Rabinovich, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323049 · Cited by 11

CAR T-cells for pediatric solid tumors: where to go from here?

Trautmann, T., Yakobian, N., & Nguyen, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10214-6 · Cited by 10

Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors

Xu, S. X., Wang, L., Ip, P., Randhawa, R. R., Benatar, T., Prosser, S. L., Lal, P., Khan, A. N., Nitya-Nootan, T., Thakor, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0138 · Cited by 10

Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity

Zheng, Q., Qiu, X., Luo, D., Ma, H., Ming, Y., Pu, W., Ai, M., He, J., & Peng, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00189 · Cited by 10

Development of Cancer Immunotherapies

DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 10

CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges

Khorasani, A. B. S., Sanaei, M., Pourbagheri‐Sigaroodi, A., Ghaffari, S. H., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108260 · Cited by 10

The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies

Holterhus, M., Altvater, B., Kailayangiri, S., & Rössig, C. (2022) · Cancers · doi:10.3390/cancers14092177 · Cited by 10

Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. (2024) · Advanced Materials · doi:10.1002/adma.202407525 · Cited by 11

Translating synthetic gene circuits into the clinic: Challenges, opportunities, and future directions

Yin, J., Ma, X., Hu, L., & Ye, H. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101425 · Cited by 11

A general logic-gating framework for CAR-T and nanocarrier cancer therapies: A cross-platform comparative analysis of logic architectures and their molecular implementation strategies

Rehorst, P., & Kros, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114583 · Cited by 10

Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 9

A minireview on multiparameter-activated nanodevices for cancer imaging and therapy

Bai, H., Peng, R., Wang, D., Sawyer, M., Fu, T., Cui, C., & Tan, W. (2020) · Nanoscale · doi:10.1039/d0nr04080k · Cited by 9

Manipulation of focal Wnt activity via synthetic cells in a double‐humanized zebrafish model of tumorigenesis

Wang, L., Long, J., Chen, H., Sun, S., Lv, K., Li, Q., & Wang, X. (2020) · International Journal of Cancer · doi:10.1002/ijc.33458 · Cited by 9

Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF‐1α regulator

Isomura, H., Taguchi, A., Kajino, T., Asai, N., Nakatochi, M., Kato, S. X., Suzuki, K., Yanagisawa, K., Suzuki, M., Fujishita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14825 · Cited by 9

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Ren, P., Zhang, C., Li, W., Wang, X., Liang, A., Yang, G., Xu, H., & Ma, P. (2022) · Advanced Biology · doi:10.1002/adbi.202101262 · Cited by 10

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Chen, L., Chen, F., Niu, H., Li, J., Pu, Y., Yang, C., Wang, Y., Huang, R., Li, K., Lei, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871661 · Cited by 11

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management

Anurogo, D., Luthfiana, D., Anripa, N., Fauziah, A. I., Soleha, M., Rahmah, L., Ratnawati, H., Wargasetia, T. L., Pratiwi, S. E., Siregar, R. N., et al. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.034 · Cited by 9

Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy

Rotiroti, M. C., Tousley, A. M., Chu, H., Herrera‐Barrera, M., Manousopoulou, A., Kim, W., Yin, Y., Parish, T., Mitchell, A., Holterhus, M., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01056-4 · Cited by 8

Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations

Rommel, P. C., Engel, N. W., Malachowski, J. K., Shukla, D., Hodson, I., Gonzales, D. M., van der Loo, J. C. M., Young, R. M., Riley, J. L., Levine, B., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012318 · Cited by 8

Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics

Li, S., Tang, H., Li, C., Ma, J., Ali, M., Dong, Q. R., Wu, J., Hui, Y., & Sun, C. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10454-5 · Cited by 9

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023)

Shi, J., Liu, X.-Y., Jiang, Y., Gao, M.-J., Yu, J., Zhang, Y.-M., & Wu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434231 · Cited by 7

Adoptive T-cell Immunotherapy: Perfecting Self-Defenses

Zur-Toledano, R., Adler, G., Shamalov, K., Tal, Y., Ankri, C., & Cohen, C. J. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_9 · Cited by 9

Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review

George, L. L., Deshpande, S., Cortese, M. J., Kendall, E. K., Chattaraj, A., Shah, Z., Zhao, J., & Anwer, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.003 · Cited by 8

Regulation of CAR transgene expression to design semiautonomous CAR-T

Głowacki, P., Tręda, C., & Rieske, P. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200833 · Cited by 9

Bioengineered therapeutic systems for improving antitumor immunity

Cao, Y., Yan, W., Yi, W., Yin, Q., & Li, Y. (2024) · National Science Review · doi:10.1093/nsr/nwae404 · Cited by 8

Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics

Grimaldi, C. M., Ibraghimov, A. R., Kießling, A., Rattel, B., Ji, C., Fuller, C. L., Brennan, F. R., Regenass-Lechner, F., Shenton, J. M., Price, K., et al. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103440 · Cited by 7

A quantitative view of strategies to engineer cell-selective ligand binding

Tan, Z. C., Orcutt-Jahns, B. T., & Meyer, A. S. (2021) · Integrative Biology · doi:10.1093/intbio/zyab019 · Cited by 7

CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation

Guo, F., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13081955 · Cited by 7

Remote control of CAR T cell therapies by thermal targetingPreprint

Miller, I. C., Sun, L.-K., Harris, A. M., Gamboa, L., Zamat, A. H., & Kwong, G. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.062703 · Cited by 8

Single-cell-guided identification of logic-gated antigen combinations for designing effective and safe CAR therapyPreprint

Madan, S., Chang, T., Harris, A. R., Liu, H., Martinez, A., Dhruba, S. R., Wang, B., Rajagopal, P. S., Sinha, S., Srinivasan, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.644074 · Cited by 7

Engineering an αCD206-synNotch Receptor: Insights into the Development of Novel Synthetic Receptors

Semeniuk, S., Qian, B., & Cachat, É. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00149 · Cited by 6

An ‘AND’ Logic Gate Nanoreactor for Metabolic Remodeling in Starvation‐Ferroptosis‐Immunotherapy of Pancreatic Cancer

Li, Y., Liu, B., Li, J., Ruan, C., Li, Z., Li, Y., Yang, Y., Li, S., Liu, X., Li, L., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202502221 · Cited by 6

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

Weber, J., Rade, M., Michael, J., Tony, L. T., Freitag, F., Spieler, P., Müller, C., Kalogirou, C., Mainz, L., Lehmann, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102400 · Cited by 7

18F-/68Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression

Yang, T., Sun, J., Huang, G., Wang, H., He, Z., Lin, S., Wang, Y., Zhuang, R., Zhang, X., Liu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02016 · Cited by 6

Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.

Miyake, N., Ochi, N., Yamane, H., Fukazawa, T., Ikeda, T., Yokota, E., Takeyama, M., Nakagawa, N., Nakanishi, H., Kohara, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.024 · Cited by 6

Intelligent tunable CAR-T cell therapy leads the new trend

Cheng, J., Liu, M., & Zhang, J. (2023) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2023.09.001 · Cited by 7

Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastomaPreprint

Choe, J. H., Watchmaker, P. B., Simic, M., Gilbert, R. D., Li, A. W., Krasnow, N. A., Carrera, D. A., Yu, W., Downey, K., Celli, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.07.425632 · Cited by 6

Coopting T cell proximal signaling molecules enables Boolean logic-gated CAR T cell controlPreprint

Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Rietberg, S. P., de la Serna, E. L., Dalton, G. N., Klysz, D. D., Weber, E. W., Kim, W., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.17.496457 · Cited by 6

Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers

Wu, Z.-L., Wang, Y., Jia, X., Wang, Y.-G., & Wang, H. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i5.603 · Cited by 5

Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes

Zhang, P., Haeseleer, F., Waltner, O. G., Gartlan, K. H., Bhise, S. S., Minnie, S. A., Adams, R. C., Yeh, A. C., Ensbey, K. S., Legg, S. R. W., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.004 · Cited by 5

Leveraging T cells for cancer immunotherapy

Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 8

Multidimensional plasticity of natural killer cells in tumours

Yang, X., Song, Z., Chen, L., Jia, Q., & Li, M. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08361-x · Cited by 5

Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target

Jamitzky, S., Altvater, B., Krekeler, C., Hoen, L., Brandes, C., Ebbinghaus, J., Richter, L., Kosel, L., Ochs, L., Farwick, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-62849-8 · Cited by 5

Methods to edit T cells for cancer immunotherapy

Lucibello, F., Menegatti, S., & Menger, L. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.048 · Cited by 5

Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors

Grover, N. S., Tschernia, N. P., Dotti, G., & Savoldo, B. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01738 · Cited by 5

Toward the clinical development of synthetic immunity to cancer

Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 9

Redirecting T cells to treat solid pediatric cancers

Rauwolf, K. K., & Rössig, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09821-5 · Cited by 5

Next generation CAR-T cells to tackle solid tumors

Abreu, T. R., Godinho‐Santos, A., Amaral, A. T., Paiva, A. A., Moreira, J. N., & Gonçalves, J. R. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114650 · Cited by 5

From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases

Bf, Y., Xu, J., & Cui, Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2627057 · Cited by 5

Obstacles and improvement strategies for CAR-T cell therapy in solid tumors

Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-04473-8 · Cited by 6

Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade

Snyder, A. J., Garrison, S. M., Kluesner, M. G., Nutt, W. S., Shasha, C., Ho, T. T. G., Marsh, S. A., Linde, M. H., Wu, F., Meyer, L. K., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adw7685 · Cited by 6

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

Wang, M., Wang, X., Jin, X., Zhou, J., Zhang, Y., Yang, Y., Liu, Y., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175118 · Cited by 4

Advances in CAR-T cell therapy for malignant solid tumors

Liu, J., Tu, X., Liu, L., & Fang, W. J. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0044 · Cited by 4

Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers

Tahmasebi, S., Khosh, E., Rostami, S. M., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_64 · Cited by 4

Functionalized DNA nanoplatform for multi-target simultaneous imaging: Establish the atlas of cancer cell species

Zhao, X., Na, N., & Ouyang, J. (2023) · Talanta · doi:10.1016/j.talanta.2023.125222 · Cited by 4

Spatial Control of CAR T Cell Activation Using Tumor-Homing Polymers

Heinze, C. M., Pichon, T. J., Wu, A. Y., Baldwin, M. L., Matthaei, J. F., Song, K., Sylvestre, M., Gustafson, J. A., White, N. J., Jensen, M. C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15442 · Cited by 4

Getting better mileage with logically primed CARs

Chen, L. C., Hou, A. J., & Chen, Y. Y. (2021) · Med · doi:10.1016/j.medj.2021.06.002 · Cited by 4

Development of a DELFIA method to detect oncofetal antigen ROR1-positive exosomes

Daikuzono, H., Yamazaki, M., Sato, Y., Takahashi, T., & Yamagata, K. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.054 · Cited by 4

Biology of CAR-T Cells

Berger, T. R., Boardman, A., Brentjens, R. J., & Maus, M. V. (2021) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_3 · Cited by 3

Tunable universal OR-gated CAR T cells for AML

Siddiqui, M. N. A., Chen, J., Huang, J., Loffredo, M. K., Lee, S., Deng, H., Li, Y., Leemans, N., Lu, T., Garrison, B. S., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117008 · Cited by 3

Detection of extracellular amyloid beta aggregates by an Aducanumab-based synNotch receptor: an in vitro proof-of-concept study

Bergo, N. J., Lee, S., Siebrand, C. J., Mayeri, Z., Andersen, J. K., & Walton, C. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07324-2 · Cited by 4

LINKing signaling domains to enhance CAR T cells

Bucher, P., & Feucht, J. (2023) · Nature Cancer · doi:10.1038/s43018-023-00538-7 · Cited by 3

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

Svec, M., Dötsch, S., Warmuth, L., Trebo, M., Fräßle, S. P., Riddell, S. R., Jaeger, U., D’Ippolito, E., & Busch, D. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268698 · Cited by 3

Engineered Cellular Therapies for the Treatment of Thoracic Cancers

Erickson, S. M., Manning, B. M., Kumar, A., & Patel, M. R. (2024) · Cancers · doi:10.3390/cancers17010035 · Cited by 4

Designer protein circuits enable safe cancer immunotherapy

Hamieh, M., & Themeli, M. (2022) · Nature · doi:10.1038/d41586-022-01528-y · Cited by 3

Engineering T cells for cancer: The evolution and future of CAR-based therapies

Unni, A., & Shankar, P. R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100892 · Cited by 4

CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?

My, B., Lia, A., Rizzo, L., Maiorano, G., Galeone, A., Palamà, I. E., & Gigli, G. (2026) · iScience · doi:10.1016/j.isci.2026.115422 · Cited by 2

Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells

Wang, S., Li, L., Xing, H., Xu, Y., Yan, Z., Ma, H., Yu, H., Ding, F., Tang, K., Tian, Z., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202503832rr · Cited by 2

Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration

Ying, H., Pan, Y., Zhu, X., & Xuan, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778197 · Cited by 2

The Most Logical Approach to Improve CAR T Cell Therapy

Lee, S.-H., & Wong, W. W. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.008 · Cited by 2

A SNIPpet of safety: a Goldilocks approach in CAR-T therapy

Benzaoui, M., Taylor, N. N., & Shah, N. N. (2022) · Cell Research · doi:10.1038/s41422-022-00682-2 · Cited by 2

CAR T-Cell Therapy in Solid Tumors: Current Review and Future Perspectives

Zheng, J. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v54i.9841 · Cited by 3

Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

Acharya, L., Garg, A., Rai, M., Kshetri, R., Grewal, U. S., & Dhakal, P. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589231191811 · Cited by 2

DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies

Torchia, M. L. G., & Moody, G. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264882 · Cited by 3

How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?

Schoenfeld, A. J., & O'Cearbhaill, R. E. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000516 · Cited by 2

Engineering solutions to design CAR-T cells

Uboldi, I., Poduval, P., & Prakash, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00001-2 · Cited by 2

Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma

Watchmaker, P. B., Colton, M., Pineo-Cavanaugh, P. L., & Okada, H. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000877 · Cited by 2

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

Huang, Y., Shao, M., Wang, Y., & Huang, H. (2022) · ImmunoMedicine · doi:10.1002/imed.1031 · Cited by 1

Promising therapeutic targets for tumor treatment: Cleaved activation of receptors in the nucleus

Fu, M., Jin, H., Zhu, D., Zhang, Q., Jiang, Z., & Yang, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104192 · Cited by 1

Evaluation of the Ligand‐Independent Activation of a VHH‐Based Anti‐CD19 SynNotch Receptor by Dual‐Luciferase Assay

Asaadi, Y., & Rahbarizadeh, F. (2025) · Analytical Science Advances · doi:10.1002/ansa.70046 · Cited by 1

“AND” Logic-Gated Biomimetic Nanoparticles to Activate Macrophage Phagocytosis for Cancer Immunotherapy

Zhang, T., Luo, J.-Q., Liu, Y., Yu, H.-H., Zhang, X., Zhuang, Z.-H., Rao, L., & Du, J. (2026) · Nano Letters · doi:10.1021/acs.nanolett.5c05413 · Cited by 1

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations

Ahn, M., Szabados, B. E., Ince, W., Kim, J., Ku, B. M., & Keenan, B. P. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517508 · Cited by 1

Synthetic Biology in Precision Medicine and Nanotechnology

Jayachandran, A., Ramakrishna, S., Shukla, R., Prithviraj, P., Kannourakis, G., & Poddar, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_37 · Cited by 1

Design and Evaluation of 68Ga-Labeled Peptide-Based PET Probes for Noninvasive Imaging of ROR1 Expression in Tumor Models

Yang, T., An, Q., Lin, S., Sun, J., Wang, Y., Chen, H., Liao, Z., Zhang, Q., Wang, H. B., Yang, G., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01128 · Cited by 1

Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases

Zhou, S., Li, Y., Zhao, J., Wang, Z., Zhou, C., Zou, Y., Li, X., Cui, J., Wu, J., & Xia, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864256 · Cited by 1

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells

Zi, G., Zhang, L., Zhou, L., Liu, X., Wang, L., Zhou, R., Zheng, P., Wei, J., Chen, X., & Wei, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02780-8 · Cited by 1

Nanomaterials Drive In Vivo CAR Immune Cells Engineering

Luo, M., Liao, K., Chang, J., Xie, J., Liang, X., Lei, Q., & Guo, W. (2026) · Advanced Materials · doi:10.1002/adma.74058 · Cited by 1

IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy

Williams, C., Zhang, P., Adams, R. C., Gong, H., Haeseleer, F., Olver, S. D., Engel, J. A., Bhise, S. S., Lee, H. J., Moreira, M. L., et al. (2026) · Blood · doi:10.1182/blood.2025032420 · Cited by 1

Chimeric Antigen Receptor (CAR) Redirected T Cells

Holzinger, A., & Abken, H. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_10 · Cited by 2

Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

Petroni, G., Kroemer, G., & Galluzzi, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.005 · Cited by 1

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

Kandav, G., & Chandel, A. (2024) · Medical Oncology · doi:10.1007/s12032-024-02491-6 · Cited by 1

Immune cell and engineering for the therapeutics

Jeong, J. H., Kim, M., & Li, H.-S. (2024) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2024.100569 · Cited by 1

DR5 CAR-NK cells demonstrate superior scalability and potent antitumor activity with favorable safety

Chen, Q., Xia, M., Tang, M., Liu, M., Yan, D., Chen, W., Xu, S. Q., Xu, Z., Chen, Y. H., Zhang, G., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.035 · Cited by 1

Innovative synthetic signaling technologies for immunotherapy

VanDyke, D., Wang, W., & Spangler, J. B. (2020) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2020.05.007 · Cited by 1

Homology mediated end joining enables efficient non-viral targeted integration of large DNA templates in primary human T cellsPreprint

Webber, B. R., Johnson, M. J., Slipek, N. J., Lahr, W. S., DeFeo, A. P., Skeate, J. G., Qiu, X., Rathmann, B., Diers, M. D., Wick, B. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.12.468427 · Cited by 1

Engineering non-cytotoxic delivery of proteins by T cells via fusion to NPC2Preprint

Saeedi, A., Bandey, I. N., Leekha, A., Fathi, M., Rezvan, A., Montalvo, M. J., Wu, K.-L., Bohat, R., Peng, W., & Varadarajan, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.24.509028 · Cited by 1

Recent advances in synNotch for biomedical applicationPreprint

Jiang, Z., Song, L., Zhang, Q., Sui, H., & Gao, C. (2024) · doi:10.22541/au.171070134.44740280/v1 · Cited by 1

Modulating AP-1 enables CAR-T cells to establish an intratumoral PD-1 + Tcf1 + stem-like reservoir and overcomes resistance to PD-1 axis blockadePreprint

Snyder, A. J., Shasha, C., Ho, T., Garrison, S. M., Wilhelm, A. R., Kluesner, M. G., Ortiz, S., Nutt, W. S., Bingham, E., Bhise, S. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648245 · Cited by 1

CAR 2.0: The Next Generation of Synthetic Receptor–Based Cellular Therapy for Cancer

Jacoby, E., & Fry, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00013-5

Abstract 6111: Reprogramming ROR1 CAR-T cells with SNIPR logic gating promote safety, while keeping anti-tumor efficacy in a tumor-bearing animal model

Deng, L., Wan, Y., Li, J., Ma, J., Zhu, D., & Zhang, H. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-6111

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 174

Research Article Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified

Cells, T., Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2016)

Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies

Lee, B. K., Wan, Y., Chin, L., Deng, L., Deng, M., Leung, T. M., Ma, J., & Zhang, H. (2022) · Cancers · doi:10.3390/cancers14153618 · Cited by 23

Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity

Vogt, K. C., Silberman, P. C., Lin, Q., Han, J. E., Laflin, A. D., Gellineau, H. A., Heller, D. A., & Scheinberg, D. A. (2025) · Science Advances · doi:10.1126/sciadv.ads3403 · Cited by 30